Major shareholder announcement - Pharma Equity Group A/S
14 Octubre 2024 - 1:17AM
UK Regulatory
Major shareholder announcement - Pharma Equity Group A/S
|
|
|
|
|
Major shareholder announcement - Pharma Equity Group
A/S
14 October 2024
Announcement No. 28
Pharma Equity Group A/S has, in accordance with section 38 of the
Capital Markets Act, received major shareholder notification that
DMZ Holding ApS has acquired shares in Pharma Equity Group A/S on
11 October 2024.
As a result, DMZ Holding ApS has increased their ownership stake
from 7,57% to over 10% in Pharma Equity Group A/S, and as of 11
October 2024, DMZ Holding ApS holds 12,93% of the voting rights and
share capital in Pharma Equity Group A/S.
For further information, please contact:
Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022
2114
Christian Vinding Thomsen, Chairman of the Board of Directors of
Pharma Equity Group A/S, phone: +45 2622 7222
|
|
|
|
|
|
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen
stock exchange, is fully dedicated to advancing the medical
projects of its subsidiary, Reponex Pharmaceuticals A/S. With an
unwavering focus on healthcare, Pharma Equity Group's primary
objective is to bring significant value to Reponex Pharmaceuticals'
medical projects.
The company is committed to providing extensive support,
resources, and expertise to drive the development and success of
these projects. As a strategic partner, Pharma Equity Group works
closely with Reponex Pharmaceuticals, prioritizing the advancement
of innovative medical solutions and breakthrough therapies. Every
effort is currently directed towards ensuring the utmost success
and impact of Reponex Pharmaceuticals' medical projects, with an
unwavering dedication to improving global healthcare outcomes. Only
when the full potential of Reponex Pharmaceuticals has been
unfolded is the intention to explore opportunities to invest in
other companies. This approach ensures a strong commitment to the
current medical projects and their development, while – on the
longer term – remaining open to new strategic investments for
continuous growth.
|
- 2024 10 14 - shareholder ann. no. 28 - UK
Pharma Equity Group A/s (LSE:0REU)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Pharma Equity Group A/s (LSE:0REU)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024